$2.38
4.23% today
Nasdaq, Sep 30, 06:51 pm CET
ISIN
KYG7S53R1049
Symbol
PROK

Prokidney Stock price

$2.48
+0.12 5.08% 1M
+1.60 183.04% 6M
+0.79 46.75% YTD
+0.56 29.17% 1Y
-6.37 71.98% 3Y
-7.63 75.47% 5Y
-7.63 75.47% 10Y
-7.63 75.47% 20Y
Nasdaq, Closing price Mon, Sep 29 2025
-0.01 0.40%
ISIN
KYG7S53R1049
Symbol
PROK
Industry

Key metrics

Basic
Market capitalization
$729.8m
Enterprise Value
$435.2m
Net debt
positive
Cash
$294.7m
Shares outstanding
292.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1,377.0 | 2,192.1
EV/Sales
821.1 | 1,307.1
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-225.6%
Return on Equity
6.2%
ROCE
-52.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$530.0k | $332.9k
EBITDA
$-175.5m | $-166.1m
EBIT
$-181.6m | $-176.8m
Net Income
$-72.5m | $-154.2m
Free Cash Flow
$-146.6m
Growth (TTM | estimate)
Revenue
- | 316.1%
EBITDA
-17.5% | 4.0%
EBIT
-18.0% | 0.9%
Net Income
-87.4% | -152.1%
Free Cash Flow
4.3%
Margin (TTM | estimate)
Gross
-
EBITDA
-33,304.7% | -49,886.5%
EBIT
-34,467.0%
Net
-13,752.2% | -46,325.1%
Free Cash Flow
-27,814.0%
More
EPS
$-0.6
FCF per Share
$-0.5
Short interest
10.5%
Employees
204
Rev per Employee
$0.0
Show more

Is Prokidney a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

Prokidney Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Prokidney forecast:

9x Buy
64%
4x Hold
29%
1x Sell
7%

Analyst Opinions

14 Analysts have issued a Prokidney forecast:

Buy
64%
Hold
29%
Sell
7%

Financial data from Prokidney

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.53 0.53
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 58 58
36% 36%
10,942%
- Research and Development Expense 124 124
12% 12%
23,430%
-176 -176
17% 17%
-33,117%
- Depreciation and Amortization 6.13 6.13
35% 35%
1,157%
EBIT (Operating Income) EBIT -182 -182
18% 18%
-34,272%
Net Profit -72 -72
87% 87%
-13,674%

In millions USD.

Don't miss a Thing! We will send you all news about Prokidney directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Prokidney Stock News

Positive
Seeking Alpha
11 days ago
I rate ProKidney a buy due to promising Phase 2 data for rilparencel in advanced CKD, strong FDA alignment, and sufficient cash runway. PROK's Phase 3 PROACT 1 study uses eGFR slope as a surrogate endpoint, with topline data expected in Q2 2027 and potential for accelerated approval. The company halted its second Phase 3 trial, saving over $150m, and expects positive REGEN-007 results to be pre...
Neutral
Seeking Alpha
22 days ago
ProKidney Corp. (NASDAQ:PROK ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT Company Participants Bruce Culleton - CEO & Director James Coulston - Chief Financial Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst Good morning, everyone. Welcome to the Morgan Stanley Global Heal...
Neutral
Seeking Alpha
27 days ago
ProKidney Corp. (NASDAQ:PROK ) Citi's Biopharma Back to School Conference September 3, 2025 10:30 AM EDT Company Participants Bruce Culleton - CEO & Director Ethan Holdaway Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Director and SMid Cap Biotech Analyst Welcome, everyone, to the next session of the Citi's Biopharma back-to-s...
More Prokidney News

Company Profile

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease (CKD), shifting the emphasis away from management of kidney failure, to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells (SRCs) prepared from a patient's own, autologous, renal cells. The company is headquartered in Winston-Salem, NC.

Head office Cayman Islands
CEO Bruce Culleton
Employees 204
Founded 2015
Website prokidney.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today